NCT05414331

WithDRawal Impact Of Postoperative Beta-Blocker

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The investigators will evaluate the impact of withdrawing beta-blocker medication after coronary artery bypass surgery with this randomized controlled trial.

Detailed description

Aim 1: The primary aim is to evaluate the impact of withdrawing BB on exercise capacity (peak oxygen consumption, VO2 max) in patients who underwent CABG. The investigators hypothesize that withdrawing BB 1 month after CABG will improve exercise capacity 2 months after CABG. Aim 2: The secondary objectives are to evaluate the impact of withdrawing BB on a MACCE (major adverse cardiac and cerebrovascular event) and fatigue-related symptoms in patients who underwent CABG. The investigators hypothesize that withdrawing BB after CABG for 1 year will be non-inferior to continuing BB in terms of MACCE incidence.

Conditions

• Coronary Artery Bypass

Interventions

Type	Name	Description
OTHER	Discontinuing all beta-blocker	All beta-blockers will be stopped 2 months after CABG

Timeline

• Start date: 2022-11-04
• Primary completion: 2024-05-02
• Completion: 2024-05-30
• First posted: 2022-06-10
• Last updated: 2025-04-06

Locations

1 site across 1 country: United States